Аудиото на този епизод може да е повредено.
How to fix it?
ОТНОСТНО ТОЗИ ЕПИЗОД
Listen to Tina Wang, Statistician, and Dr. Paul Schuette, Deputy Division Director, in the Office of Biostatistics Division of Analytics and Informatics within FDA’s Center for Drug Evaluation and Research discuss FDA’s experiences with a centralized statistical monitoring tool.
Английски
САЩ
ТЪРСЕНЕ на МИНАЛИ ЕПИЗОДИ
Търсене в минали епизоди на FDA CDER Small Business and Industry Assistance (SBIA) Chronicles.
ДРУГИ ЕПИЗОДИ В ТОЗИ ПОДКАСТ
The CDER NextGen Portal (or the “Portal” for short) has made it easier than ever for regulated industry to communicate with the FDA.
The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities
Continuous manufacturing (CM) technology has the potential to improve product quality and reliability, lower manufacturing costs, reduce waste, decrease inventory, and increase manufacturing flexibility and agility in response to product demand.
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development
Опровержение: Подкастът и произведенията на изкуството, вградени на тази страница, са от U.S. Food and Drug Administration, Center for Drug Evaluation and Research, което е собственост на неговия собственик и не е свързано с или одобрено от Listen Notes, Inc.
РЕДАКТИРАНЕ
Благодарим Ви, че помогате да поддържаме базата данни за подкастове актуална.
